Relmada Therapeutics To Participate At The Wells Fargo 21St Annual Healthcare Conference

2026-09-01 08:02:15

(MENAFN- GlobeNewsWire - Nasdaq) CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD,“Relmada” or the“Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.

Wells Fargo 21st Annual Healthcare Conference Details
Format: One-on-one Meetings
Date: September 8 - 10, 2026

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

For more information, visit

Investor Contact:
Brian Ritchie
LifeSci Advisors
...

Media Inquiries:
Corporate Communications
...

MENAFN01092026004107003653ID1111606307

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Relmada Therapeutics To Participate At The Wells Fargo 21St Annual Healthcare Conference

More Story